-

Aldevron Announces Second Breakthrough Symposium

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus.

The three-day Breakthrough Symposium will welcome scientific speakers focused on pioneering advances and innovative technologies in gene and cell therapies, genetic and regenerative medicine, gene editing and more. Additionally, patients and advocates will speak on these advancements and how they are transforming medicine.

Organized by Aldevron, the symposium will feature several distinguished industry and academic researchers such as Stephen Johnston, Ph.D., Center Director and Professor, Biodesign Center for Innovations in Medicine, Arizona State University; Jill Weimer, Senior VP of Discovery Science, Amicus Therapeutics and Senior Director of Therapeutic Development, Sanford Research; and Nicole Boice, Co-Founder, RARE-X, and Founder, Global Genes.

“Aldevron is honored to work with some of the most innovative companies, academic institutions, and government laboratories in biotechnology today. Our focus continues to be our clients and the patients they serve, and we are proud to provide a platform to bring these two communities together,” said Michael Chambers, Aldevron’s CEO. “The theme 'pioneering' is a nod not only to our industry, but to Aldevron’s home base. North Dakota is guided by a pioneering spirit, making it the perfect place for to host a conference focused on how we continue to make breakthroughs throughout the industry.”

To learn more about the current line-up of speakers, submit a poster abstract or to register, visit BreakthroughSymposium.com

About Aldevron
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source® quality system. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wisc., and Freiburg, Germany.

Contacts

Ellen Shafer
Senior Director of Marketing and Communications
ellen.shafer@aldevron.com
701-551-8704

Aldevron

Details
Headquarters: Fargo, ND, USA
CEO: Kevin Ballinger
Employees: 500+
Organization: PRI

Release Versions

Contacts

Ellen Shafer
Senior Director of Marketing and Communications
ellen.shafer@aldevron.com
701-551-8704

Social Media Profiles
More News From Aldevron

Aldevron Expands Commercial Leadership Team With Addition of Two Industry Veterans

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, the world’s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales. Thompson-Webb will be responsible for leading Aldevron’s worldwide sales and marketing strategy where she will utilize her 30 years of industry experience to drive strategic growth and service initiatives. Thompson-Webb will report to Ke...

Aldevron Adds Self-Amplifying RNA to its Product Portfolio

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced today the addition of three reporter Self-amplifying RNA (saRNA) products to its growing catalog: AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™. Alphavirus-derived saRNA encodes nonstructural proteins that enable self-replication, thereby allowing lower doses for genetic medicines and vaccines, and saRNA is being used to suppo...

Aldevron Now Offering AAV Rep/Cap Plasmids for Viral Vector Production

FARGO, N.D.--(BUSINESS WIRE)--Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through...
Back to Newsroom